Adverse event management in patients with relapsed and refractory multiple myeloma taking pomalidomide plus low-dose dexamethasone: A pooled analysis.

@article{Moreau2017AdverseEM,
  title={Adverse event management in patients with relapsed and refractory multiple myeloma taking pomalidomide plus low-dose dexamethasone: A pooled analysis.},
  author={Philippe Moreau and Meletios Athanasios Dimopoulos and Paul G Richardson and D S Siegel and Michele Cavo and P. Poggi – Corradini and Katja C. Weisel and Michel Delforge and Peter J O'Gorman and Kevin W. Song and Christine I. Chen and Nizar Jacques Bahlis and Albert Oriol and Markus Hansson and Martin F Kaiser and Pekka Anttila and Reinier A. P. Raymakers and Cristina Jo{\~a}o and Gordon Cook and Lars Axel Sternas and Tsvetan Biyukov and Ana Slaughter and Kevin Hong and Jennifer Herring and Xin Yu and Mohamed H. Zaki and Jes{\'u}s F San-Miguel},
  journal={European journal of haematology},
  year={2017},
  volume={99 3},
  pages={199-206}
}
OBJECTIVES Heavily pretreated patients with relapsed and refractory multiple myeloma are susceptible to treatment-related adverse events (AEs). Managing AEs are important to ensure patients continue therapy long enough to receive the best clinical benefit. Data from the MM-002, MM-003, and MM-010 trials were pooled to further characterize the safety profile of pomalidomide plus low-dose dexamethasone and AE management. METHODS This analysis included 1088 patients who received ≥ 2 prior… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 1 time over the past 90 days. VIEW TWEETS